Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICPi) have revolutionized the treatment of many types of cancers.ICPis work by blocking pathways, called checkpoints, and these checkpoint pathways are mechanisms for the human immune system to control the immune response.The immune checkpoint proteins, cytotoxic T lymphocyte-associated 4 (CTLA-4) and programmed death 1 (PD-1), are receptors that are expressed on the surface of cytotoxic T cells that interact with their ligands-CD80/CD86 in the case of CTLA-4, and programmed death ligand-1 in the case of PD-1.These pathways can be co-opted to help cancer cells evade cytotoxic T cell-mediated death. 1 ICPis prevent receptors and ligands from binding to each other, thereby disrupting signaling.1 Currently, there are several ICPis that have been approved by the US Food and Drug Administration.Ipilimumab, an anti-CTLA-4 antibody, was the first agent approved for use in patients with advanced melanoma.2 Pembrolizumab and nivolumab target PD-1 and have been approved for the treatment of melanoma, metastatic non-small-cell lung cancer, head and neck squamous cancers, urothelial carcinoma, gastric adenocarcinoma, and mismatch repair-deficient solid tumors as well as classical Hodgkin lymphoma.2
No takes yet. Share an insight, caveat, or question.
Brahmer et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: